ClinicalTrials.gg
Active, not recruitingNCT05735327ENTIRETYUpdated Apr 13, 2026

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

An observational study in Non-small Cell Lung Cancer (NSCLC), sponsored by Takeda. Active, not recruiting at 12 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Takeda · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.

Planned enrollment
7th of 10
50 · median 94
Started
2023
the only one that year
Observational
10 of 31
1 open now
Registered
29th of 31
by date

Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2023, is one of 10 observational ones, and was the 29th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, or all of them as a file.
02

Study summary

This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib. Another aim is to learn about the overall rate of participants who respond to the treatment with brigatinib.

Participants will receive brigatinib as part of their normal clinical practice. Data will be collected during regular visits to the hospital (a total of up to 12 visits is planned throughout study duration).

Read the detailed description

This is a non-interventional, prospective study of Polish participants with ALK positive NSCLC receiving Brigatinib as their first line of treatment in the scope of routine clinical practice within the frames of National Drug Program (NDP). This study will evaluate progression-free survival (from the time of the first dose of brigatinib).

This study will enrol approximately 50 participants. Participants will be enrolled in the following cohort to be observed at baseline, and every 3 months up to 33 months:

  • Brigatinib

This multi-center trial will be conducted in Poland. The overall duration of the study will include approximately 18 months of enrolment and approximately 33 months of data collection and follow-up.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants diagnosed with ALK positive NSCLC who received brigatinib in first-line treatment in Poland.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (aged ≥18) ALK positive NSCLC participants receiving brigatinib as a treatment in the scope of NDP.
  2. Participants willing to participate in the study and signed ICF.

Exclusion criteria

Exclusion Criteria

  1. Current or planned participation in an interventional clinical trial for ALK positive non-small cell lung cancer (NSCLC).
  2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Brigatinib

    Participants receiving Brigatinib as part of their first-line treatment in scope of their routine clinical practice within the frames of National Drug Program (NDP) will be observed at baseline, and every 3 months (± 1 month) at routine follow-up for up to 33 months.

    Drug: No intervention

Interventions

  • DrugNo intervention

    As this is an observational study, no intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Real-World Progression Free Survival (rwPFS)

    rwPFS is defined as the time from starting treatment to the time of radiographic progression according to Response evaluation criteria in solid tumors (RECIST) v1.1 criteria.

    Time frame: Up to 33 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from starting treatment with brigatinib until death due to any cause or loss to follow-up.

    Time frame: Up to 33 months

  2. Real-World Overall Response Rate (rwORR)

    rwORR (including intracranial response) is defined as the sum of the partial and complete response according to RECIST version 1.1. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm.

    Time frame: Up to 33 months

  3. Time to Discontinuation (TTD)

    TTD is defined as the time from starting treatment to the time to treatment discontinuation due to any cause.

    Time frame: Up to 33 months

07

Study locations

12 sites
  • Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii
    Wroclaw, Dolnoslskie 53-413, Poland
  • Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu.
    Poznan, Greater Poland Voivodeship 60-355, Poland
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
    Poznan, Greater Poland Voivodeship 60-569, Poland
  • Centrum Onkologii im.Prof. F. Lukaszczyka w Bydgoszczy
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie- Panstwowy Instytut Badawczy Oddzial w Krakowie
    Krakow, Lesser Poland Voivodeship 31-115, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie
    Krakow, Lesser Poland Voivodeship 31-202, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
    Lublin, Lublin Voivodeship 20-954, Poland
  • Instytut Gruzlicy i Chorob Pluc
    Warsaw, Masovian Voivodeship 01-138, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Panstwowy Instytut Badawczy
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Podkarpackie Centrum Chorob Pluc
    Rzeszów, Podkarpackie Voivodeship 35-241, Poland
  • Centrum Pulmonologii i Torakochirurgii w Bystrej
    Bystra, Slskie 43-360, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 2 im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Lodzi Centralny Szpital Weteranow
    Lodz, Łódź Voivodeship 90-549, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2027, 47 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 47 months is close to that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2023
First posted
Feb 21, 2023
StartActual
May 22, 2023
Primary completionEst.
Apr 26, 2027
CompletionEst.
Apr 26, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05735327
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
May 22, 2023
Primary completion
Apr 26, 2027 (estimated)
Completion
Apr 26, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion